Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of Docetaxel and Prednisone, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Castrate-Resistant Prostate Cancer

NCT01234025 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01234025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01234025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of Docetaxel and Prednisone, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Castrate-Resistant Prostate Cancer
Lead sponsor
Ionis Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2010
Completion date
December 31, 2013
Enrollment
113 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

castrate-resistant prostate cancer